Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension
Authors:
- 21 September 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 33 (3) , 207-213
Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.Keywords
This publication has 37 references indexed in Scilit:
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2015
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetesDiabetes & Vascular Disease Research, 2015
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetesDiabetologia, 2015
- SGLT2 inhibitors: their potential reduction in blood pressureJournal of the American Society of Hypertension, 2015
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and HypertensionDiabetes Care, 2014
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2014
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysisJournal of the American Society of Hypertension, 2014
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitusCardiovascular Diabetology, 2014
- Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature reviewDiabetes, Metabolic Syndrome and Obesity, 2013
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004